Navigation Links
Shire plc: Long Term Incentive Plan
Date:3/26/2008

BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, March 26 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announces the release on March 25, 2008, of ordinary shares of 5 pence in the capital of Shire plc ("Shares") in connection with the Shire Long Term Incentive Plan ("LTIP").

In accordance with the rules of the LTIP, the following Shares were released:

Name of PDMR Number of Shares

Released

Mr M Emmens 75,408

Mr A Russell 46,634

Ms T May 30,746

Mr J Rus 23,365

Ms A Graham 18,843

The LTIP awards were subject to performance criteria and, in accordance with the rules of the LTIP, the number of Shares to be released was approved by the Remuneration Committee in 2007. Whilst the performance period is measured over three years, the Shares are only released after the fourth anniversary of the grant. The LTIP awards were satisfied by way of a cash payment, being a sum equal to the cash equivalent of the number of Shares released. The cash equivalent was determined by using the middle market quotation of the Shares on the business day preceding the day on which entitlement arose.

This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.
T May

Company Secretary

Notes to editors

Shire plc Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the Specialist physician. Shire focuses its business on attention deficit and Hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.


'/>"/>
SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Shire plc: IFRS Results for the Year Ending December 31, 2007
2. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
3. Shire plc: Correction Re Website
4. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
5. Shire Engages Palio
6. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
7. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
10. Shire plc: Board Changes
11. David Mott Appointed Non Executive Director at Shire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 ContraVir Pharmaceuticals, Inc. ... the development and commercialization of targeted antiviral therapies, announced ... Investor Conference 2016, to be held February 8-9, 2016, ... Group,s 2016 Disruptive Growth & Healthcare Conference, taking place ... 10-11, 2016. James Sapirstein , Chief Executive ...
(Date:2/4/2016)... February 4, 2016 Strasbourg, France ... Inc. --> Strasbourg, France , to ... PharmaVentures is pleased to announce that it acted as ... manufacturing unit in Strasbourg, France , to ... --> --> Transgene (Euronext: TNG), a ...
(Date:2/3/2016)... 3, 2016  With the growing need for ... is underway, therapies such as monoclonal antibodies, recombinant ... host of indications are in high demand. Conventionally ... development and production of these therapeutics. However, due ... high costs, novel approaches and novel expression systems ...
(Date:2/3/2016)... ... February 03, 2016 , ... Aerocom, a world-leading supplier of ... North American healthcare market. , Aerocom Healthcare, LLC will be based in Denver, ... provide new pneumatic tube systems or expand existing systems within the U.S. and ...
Breaking Biology Technology:
(Date:1/20/2016)... MINNETONKA, Minn. , Jan. 20, 2016   ... that supports the entire spectrum of clinical research, is ... in 2015. MedNet,s significant achievements are the result of ... of) iMedNet eClinical , it,s comprehensive, ... --> --> Key MedNet growth ...
(Date:1/13/2016)... ALBANY, New York , January 13, 2016 /PRNewswire/ ... Transparency Market Research has published a new market report ... Share, Growth, Trends, and Forecast, 2015 - 2023. According to ... mn in 2014 and is anticipated to reach US$1,625.8 ... from 2015 to 2023. In terms of volume, the ...
(Date:1/8/2016)... and MANCHESTER, United Kingdom , ... a developer of innovative sensor-based diagnostic products, today announced the ... by new and existing investors.  Proceeds from the financing will ... Scanner , a hand-held device for detecting early-stage pressure ulcers. ... Ireland after receiving CE Mark approval. The ...
Breaking Biology News(10 mins):